Heilongjiang ZBD Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Heilongjiang ZBD Pharmaceutical's earnings have been declining at an average annual rate of -2.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 6.5% per year. Heilongjiang ZBD Pharmaceutical's return on equity is 6.1%, and it has net margins of 18.8%.
Key information
-2.9%
Earnings growth rate
-5.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 6.5% |
| Return on equity | 6.1% |
| Net Margin | 18.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Heilongjiang ZBD Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,728 | 512 | 858 | 70 |
| 31 Dec 23 | 3,144 | 473 | 1,002 | 80 |
| 30 Sep 23 | 4,330 | 508 | 1,077 | 75 |
| 30 Jun 23 | 4,322 | 290 | 1,016 | 69 |
| 31 Mar 23 | 4,743 | 282 | 1,030 | 74 |
| 31 Dec 22 | 4,214 | 185 | 885 | 71 |
| 30 Sep 22 | 4,740 | 243 | 796 | 61 |
| 30 Jun 22 | 4,975 | 295 | 884 | 57 |
| 31 Mar 22 | 4,404 | 335 | 1,007 | 55 |
| 31 Dec 21 | 4,127 | 332 | 997 | 55 |
| 30 Sep 21 | 4,332 | 438 | 1,108 | 70 |
| 30 Jun 21 | 3,671 | 528 | 1,069 | 71 |
| 31 Mar 21 | 3,509 | 465 | 1,064 | 84 |
| 31 Dec 20 | 3,404 | 436 | 1,089 | 81 |
| 30 Sep 20 | 2,956 | 312 | 1,142 | 67 |
| 30 Jun 20 | 3,186 | 356 | 1,166 | 75 |
| 31 Mar 20 | 3,125 | 366 | 1,077 | 86 |
| 31 Dec 19 | 3,292 | 409 | 1,197 | 87 |
| 30 Sep 19 | 2,915 | 428 | 1,156 | 92 |
| 30 Jun 19 | 2,987 | 451 | 1,199 | 92 |
| 31 Mar 19 | 2,960 | 474 | 1,329 | 75 |
| 01 Jan 19 | 2,781 | 462 | 1,248 | 91 |
| 30 Sep 18 | 3,190 | 539 | 1,311 | 103 |
| 30 Jun 18 | 3,235 | 570 | 1,187 | 140 |
| 31 Mar 18 | 3,199 | 561 | 1,072 | 118 |
| 31 Dec 17 | 3,137 | 521 | 984 | 94 |
| 30 Sep 17 | 2,858 | 485 | 1,075 | 57 |
| 30 Jun 17 | 2,629 | 501 | 1,133 | 0 |
| 31 Mar 17 | 2,529 | 560 | 1,038 | 0 |
| 31 Dec 16 | 2,391 | 510 | 994 | 0 |
| 30 Sep 16 | 2,262 | 670 | 796 | 0 |
| 30 Jun 16 | 2,257 | 554 | 897 | 0 |
| 31 Mar 16 | 2,274 | 625 | 880 | 0 |
| 31 Dec 15 | 2,073 | 585 | 842 | 0 |
| 30 Sep 15 | 1,928 | 501 | 697 | 0 |
| 30 Jun 15 | 1,598 | 496 | 472 | 0 |
| 31 Mar 15 | 1,659 | 495 | 408 | 0 |
| 31 Dec 14 | 1,593 | 477 | 383 | 0 |
| 31 Dec 13 | 1,415 | 437 | 321 | 0 |
Quality Earnings: 603567 has high quality earnings.
Growing Profit Margin: 603567's current net profit margins (18.8%) are higher than last year (5.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603567's earnings have declined by 2.9% per year over the past 5 years.
Accelerating Growth: 603567's earnings growth over the past year (81.8%) exceeds its 5-year average (-2.9% per year).
Earnings vs Industry: 603567 earnings growth over the past year (81.8%) exceeded the Pharmaceuticals industry -1.6%.
Return on Equity
High ROE: 603567's Return on Equity (6.1%) is considered low.